Contravisory Investment Management Inc. Makes New $221,000 Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Contravisory Investment Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 10,009 shares of the company’s stock, valued at approximately $221,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Stifel Financial Corp increased its holdings in shares of Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after buying an additional 23,283 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,218 shares in the last quarter. Sio Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $24,314,000. CWA Asset Management Group LLC bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $3,340,000. Finally, Two Sigma Advisers LP raised its position in shares of Teva Pharmaceutical Industries by 15.3% in the 3rd quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock worth $18,642,000 after acquiring an additional 137,000 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on TEVA shares. Barclays boosted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.88.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Down 1.2 %

Teva Pharmaceutical Industries stock opened at $21.68 on Friday. The stock’s fifty day moving average is $19.14 and its two-hundred day moving average is $18.16. Teva Pharmaceutical Industries Limited has a 1-year low of $10.83 and a 1-year high of $22.80. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.